Elasomeran – Communicable Diseases Research

Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies

투석 환자에서 BNT162b2에 이어 mRNA-1273으로 이종 면역화: 혈청전환 및 중화항체 존재

Article

Published on 2022-05-252022-09-12
Journal: Nephrology, dialysis, transplantation : official p [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] acute respiratory syndrome Analysis anti-SARS-CoV-2 antibodies antibody BNT162b2 boost booster Cambridge Characteristics Concentration coronavirus COVID-19 cut-off dialysis disease dose Efficacy Elasomeran Elecsy Genscript Germany heterologous immunization high risk Humoral immunity immunoreactivity Immunosuppression Infection Mainz Moderna Mortality mRNA vaccine mRNA-1273 mRNA-1273 booster neutralization Neutralization assay Neutralizing antibodies neutralizing antibody of BNT162b2 Patient patients performed plaque reduction neutralization PRNT receiver receiving renal replacement therapy ROC Roche Diagnostics SARS-CoV-2 SARS-CoV-2 spike Seroconversion surrogate Test the SARS-CoV-2 titre Tozinameran USA vaccination virus-neutralizing was measured was reduced were measured were used while wild-type SARS-CoV-2 York
[DOI] 10.1093/ndt/gfac018 PMC 바로가기 [Article Type] Article

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

3 개의 승인 된 siRNA (Patisiran) 및 mRNA (COVID-19 백신) 약물에 사용 된 지질 나노 입자 기술의 차이

Review

Published on 2021-12-012022-08-31
Journal: Drug metabolism and pharmacokinetics [Category] MERS, 치료제,